Elizabeth Miller

Summary

Affiliation: Health Protection Agency
Country: UK

Publications

  1. doi request reprint Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine
    Elizabeth Miller
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Services, Colindale, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
    Vaccine 29:9127-31. 2011
  2. doi request reprint Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study
    Elizabeth Miller
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, Colindale, London, UK
    Lancet Infect Dis 11:760-8. 2011
  3. pmc Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England
    Nick Andrews
    Statistics Unit, Hepatitis, and Blood Safety Department, Health Protection Agency Centre for Infections, London, England
    J Infect Dis 203:32-9. 2011
  4. ncbi request reprint Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis
    Elizabeth Miller
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, Colindale, London NW9 5EQ, UK
    BMJ 346:f794. 2013
  5. pmc Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease
    Alessia Melegaro
    DONDENA Centre for Research on Social Dynamics, Bocconi University, Via Guglielmo Rontgen, Milan, Italy
    BMC Infect Dis 10:90. 2010
  6. pmc The epidemiology of subacute sclerosing panencephalitis in England and Wales 1990-2002
    C Miller
    Immunisation Department, Communicable Disease Surveillance Centre, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK
    Arch Dis Child 89:1145-8. 2004
  7. ncbi request reprint Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom
    E Miller
    Immunisation Department, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London, UK
    Am J Epidemiol 165:704-9. 2007
  8. doi request reprint Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study
    Elizabeth Miller
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency Centre for Infections, London, UK
    Lancet 375:1100-8. 2010
  9. pmc No evidence of an association between MMR vaccine and gait disturbance
    E Miller
    Immunisation Division, Public Health Laboratory Service, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK
    Arch Dis Child 90:292-6. 2005
  10. pmc Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine
    Ray Borrow
    Vaccine Evaluation Unit, Health Protection Agency, Manchester Medical Microbiology Partnership, P O Box 209, Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom
    Clin Vaccine Immunol 17:154-9. 2010

Collaborators

Detail Information

Publications147 found, 100 shown here

  1. doi request reprint Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine
    Elizabeth Miller
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Services, Colindale, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
    Vaccine 29:9127-31. 2011
    ..VE for serotypes 1 and 3 was 62% and 66% respectively although confidence intervals spanned zero. IPD due to PCV13-only serotypes halved in children under 2 years in the study period...
  2. doi request reprint Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study
    Elizabeth Miller
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, Colindale, London, UK
    Lancet Infect Dis 11:760-8. 2011
    ..We assess the effect of the PCV7 vaccination on VT and NVT disease in England and Wales...
  3. pmc Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England
    Nick Andrews
    Statistics Unit, Hepatitis, and Blood Safety Department, Health Protection Agency Centre for Infections, London, England
    J Infect Dis 203:32-9. 2011
    ..The use of a squalene-containing (AS03) pandemic vaccine for high-risk groups in England allowed vaccine effectiveness (VE) of such novel oil-in-water adjuvanted vaccine to be evaluated...
  4. ncbi request reprint Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis
    Elizabeth Miller
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, Colindale, London NW9 5EQ, UK
    BMJ 346:f794. 2013
    ..To evaluate the risk of narcolepsy in children and adolescents in England targeted for vaccination with ASO3 adjuvanted pandemic A/H1N1 2009 vaccine (Pandemrix) from October 2009...
  5. pmc Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease
    Alessia Melegaro
    DONDENA Centre for Research on Social Dynamics, Bocconi University, Via Guglielmo Rontgen, Milan, Italy
    BMC Infect Dis 10:90. 2010
    ..However the long term effects of PCV are still unclear, as beneficial direct and herd immunity effects might be countered by serotype replacement...
  6. pmc The epidemiology of subacute sclerosing panencephalitis in England and Wales 1990-2002
    C Miller
    Immunisation Department, Communicable Disease Surveillance Centre, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK
    Arch Dis Child 89:1145-8. 2004
    ..To assess the impact of measles/mumps/rubella (MMR) vaccine on the epidemiology of subacute sclerosing panencephalitis (SSPE) in England and Wales...
  7. ncbi request reprint Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom
    E Miller
    Immunisation Department, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London, UK
    Am J Epidemiol 165:704-9. 2007
    ..48, 95% confidence interval: 0.88, 2.50) as occurred with Urabe-containing vaccines. This study demonstrates the power of active postmarketing surveillance to identify or exclude events too rare to be detected in prelicensure trials...
  8. doi request reprint Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study
    Elizabeth Miller
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency Centre for Infections, London, UK
    Lancet 375:1100-8. 2010
    ....
  9. pmc No evidence of an association between MMR vaccine and gait disturbance
    E Miller
    Immunisation Division, Public Health Laboratory Service, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK
    Arch Dis Child 90:292-6. 2005
    ..MMR vaccine has been reported to cause gait disturbance, and this possible association has been claimed to support the MMR-causes-autism theory...
  10. pmc Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine
    Ray Borrow
    Vaccine Evaluation Unit, Health Protection Agency, Manchester Medical Microbiology Partnership, P O Box 209, Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom
    Clin Vaccine Immunol 17:154-9. 2010
    ....
  11. pmc Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales
    Shamez N Ladhani
    Immunisation Department, Health Protection Agency Colindale, London, UK
    Emerg Infect Dis 19:61-8. 2013
    ..4% (58/1,332) but higher for meningitis (11.0%) and children with comorbidities (9.1%). Thus, comorbidities were more prevalent in children with IPD caused by non-PCV13 serotypes and were associated with increased case fatality...
  12. doi request reprint Impact of the 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in infants younger than 90 days in England and wales
    Shamez N Ladhani
    Health Protection Services Colindale, Health Protection Agency, Manchester Royal Infirmary, Manchester, United Kingdom
    Clin Infect Dis 56:633-40. 2013
    ....
  13. pmc Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study
    Stefan Flasche
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom
    PLoS Med 8:e1001017. 2011
    ....
  14. doi request reprint Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom
    David Goldblatt
    Immunobiology Unit, UCL Institute of Child Health, London, United Kingdom
    Pediatr Infect Dis J 29:401-5. 2010
    ..This study was conducted to establish the immunogenicity of licensed PCV (Prevenar) at a reduced, 2 priming dose schedule (2+1) and to evaluate functional responses in the context of vaccine effectiveness...
  15. pmc Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom
    Jo Southern
    Immunisation Department, Centre for Infections, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom
    Clin Vaccine Immunol 16:194-9. 2009
    ..This study demonstrates that NeisVac-C and Menjugate generate good immunogenicity after the first dose at 2 months of age when coadministered with PCV7 and Pediacel and merit further investigation in single-dose priming strategies...
  16. ncbi request reprint Reactogenicity of meningococcal C conjugate vaccines when administered at the same time as, or a month prior to or after, tetanus and diphtheria booster vaccinations
    Jo Southern
    Immunisation Department, Centre for Infections, Health Protection Agency, Colindale, London, UK
    Hum Vaccin 2:237-42. 2006
    ..This single blind study was conducted to address safety concerns regarding coadministration of diphtheria/ tetanus (DT,Td) boosters and meningococcal C conjugate (MCC) vaccines containing diphtheria or tetanus conjugate proteins...
  17. pmc Safety and immunogenicity of coadministering a combined meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine with 7-valent pneumococcal conjugate vaccine and measles, mumps, and rubella vaccine at 12 months of age
    Elizabeth Miller
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom
    Clin Vaccine Immunol 18:367-72. 2011
    ..The United Kingdom infant immunization schedule now recommends that these three vaccines may be offered at one visit at between 12 and 13 months of age...
  18. pmc Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and Wales
    Nick Andrews
    Statistics, Modelling and Economics Department, Health Protection Services, Health Protection Agency, London, United Kingdom
    PLoS ONE 6:e28435. 2011
    ..We estimated the effectiveness of PCV-7 against IPD...
  19. ncbi request reprint Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom
    Cressida Auckland
    Immunisation Department, Centre for Infections, Health Protection Agency, Manchester Royal Infirmary, Manchester, United Kingdom
    J Infect Dis 194:1745-52. 2006
    ..The meningococcal serogroup C conjugate (MCC) vaccine was introduced into the United Kingdom with licensure based on immunogenicity data not efficacy data...
  20. pmc Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity
    Helen Campbell
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK
    Clin Vaccine Immunol 17:840-7. 2010
    ..Modeling suggested that protection against carriage persists for at least 3 years and predicted the stabilization of serogroup C disease at low levels (fewer than 50 cases per year) up to 2015-2016...
  21. pmc Seroprevalence of influenza A(H1N1)pdm09 virus antibody, England, 2010 and 2011
    Katja Hoschler
    Respiratory Virus Unit, Virus Reference Department, Microbiology Services Colindale, Health Protection Agency, 61 Colindale Ave, London, NW9 5HT, UK
    Emerg Infect Dis 18:1894-7. 2012
    ..Population-based seroepidemiology confirms that the third wave of influenza A(H1N1)pdm09 virus circulation was associated with a shift in age groups affected, with the highest rate of infection in young adults...
  22. doi request reprint Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United kingdom
    Helen Findlow
    Vaccine Evaluation Unit, Health Protection Agency, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, United Kingdom
    Pediatr Infect Dis J 31:616-22. 2012
    ..Recent data have demonstrated that 2 of the 3 MCC vaccines showed potential for use as a single priming dose in infancy...
  23. doi request reprint Invasive pneumococcal disease among HIV-positive individuals, 2000-2009
    Zheng Yin
    HIVand STI Department, Health Protection Agency, London, UK
    AIDS 26:87-94. 2012
    ....
  24. pmc 7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement?
    Yoon Hong Choi
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom
    PLoS ONE 6:e26190. 2011
    ..However, recent surveillance data show a more rapid replacement of PCV7 IPD cases by non-PCV7 IPD cases than was seen in the US...
  25. ncbi request reprint Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales
    Caroline L Trotter
    Immunisation Department, Health Protection Agency Centre for Infections, London, UK
    Hum Vaccin 2:68-73. 2006
    ..The inclusion of a booster dose is likely to improve the impact of the MCC program and reducing the number of doses in infancy will improve cost-effectiveness and create space in the schedule for the addition of other vaccines...
  26. pmc Age-specific incidence of A/H1N1 2009 influenza infection in England from sequential antibody prevalence data using likelihood-based estimation
    Marc Baguelin
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom
    PLoS ONE 6:e17074. 2011
    ..The method provides a more accurate and continuous measure of incidence than achieved by comparing prevalence in samples grouped by time period...
  27. pmc The impact of specific and non-specific immunity on the ecology of Streptococcus pneumoniae and the implications for vaccination
    Stefan Flasche
    Immunisation, Hepatitis and Blood Safety Department, Public Health England, 61 Colindale Avenue, Colindale, London NW9 5EQ, UK, Department of Mathematics and Statistics, Strathclyde University, 26 Richmond Street, Glasgow G1 1XH, UK, Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK, Institute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, UK, Health Protection Scotland, 5 Cadogan Street, Glasgow G2 6QE, UK, International Prevention Research Institute, 95 cours Lafayette, Lyon 69006, France
    Proc Biol Sci 280:20131939. 2013
    ..Hence, if vaccine effects are insufficient to control the majority of serotypes at the same time, then exploiting the competitive pressure by selective vaccination can help control the most pathogenic serotypes. ..
  28. pmc Changes in molecular epidemiology of streptococcus pneumoniae causing meningitis following introduction of pneumococcal conjugate vaccination in England and Wales
    Bruno Pichon
    Respiratory and Systemic Infection Laboratory, Health Protection Agency, London, United Kingdom
    J Clin Microbiol 51:820-7. 2013
    ....
  29. pmc Mathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales
    Yoon Hong Choi
    Health Protection Services Colindale, Health Protection Agency, London, United Kingdom
    PLoS ONE 7:e39927. 2012
    ....
  30. doi request reprint The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England
    Albert Jan van Hoek
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Services, Colindale, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
    J Infect 65:17-24. 2012
    ..Three years of post 7-valent pneumococcal conjugate vaccine (PCV7) data was included to investigate the herd protection effects...
  31. pmc Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults
    Jo Southern
    Immunisation Department, Communicable Disease Surveillance Centre, Health Protection Agency, 61 Colindale Ave, Colindale, London, United Kingdom
    Clin Diagn Lab Immunol 11:1100-4. 2004
    ..The study shows that MCC-TT is safe and immunogenic in naive and previously MACP-vaccinated adults, though the magnitude and persistence of postvaccination SBA responses in the latter group were lower...
  32. doi request reprint Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales
    Nick J Andrews
    Statistics, Modelling and Economics Department, Health Protection Services, Health Protection Agency, London, United Kingdom
    Vaccine 30:6802-8. 2012
    ..Based on the VE estimates PPV23 was still considered a cost-effective intervention for the low risk elderly...
  33. pmc Accelerating control of pertussis in England and Wales
    Helen Campbell
    Health Protection Agency, London, UK
    Emerg Infect Dis 18:38-47. 2012
    ..e., <3 months of age), teenagers, and adults. Future vaccine program changes may be beneficial, but additional detail is required to inform such decisions...
  34. pmc Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in inf
    Jo Southern
    Immunisation Department, Centre for Infections, Health Protection Agency, London NW9 5EQ, United Kingdom
    Clin Vaccine Immunol 14:1328-33. 2007
    ..15 microg/ml in about 90% of individuals. A booster dose of Hib vaccine given after the first year of life should provide long-lasting protection...
  35. ncbi request reprint Morbidity and mortality of pneumococcal meningitis and serotypes of causative strains prior to introduction of the 7-valent conjugant pneumococcal vaccine in England
    Alan P Johnson
    Department of Healthcare Associated Infection and Antimicrobial Resistance, Health Protection Agency Centre for Infections, London, NW9 5EQ, UK
    J Infect 55:394-9. 2007
    ....
  36. doi request reprint Immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer in the United Kingdom
    Jessica Bate
    Dept of Child Health, St George s, University of London, London, England
    Clin Infect Dis 51:e95-104. 2010
    ..Children with cancer have an increased susceptibility to influenza infection. The objective of this study was to assess the immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer...
  37. doi request reprint Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines
    Nick J Andrews
    Department of Statistics, Modelling and Economics, Health Protection Services, Health Protection Agency, Colindale, London NW9 5EQ, UK
    Vaccine 29:7913-9. 2011
    ..Reduction in the interval between doses for earlier protection would be at the cost of reduced immunogenicity. The effect of seasonal vaccine on immunogenicity merits further investigation...
  38. pmc Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes
    Albert Jan van Hoek
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom
    PLoS ONE 7:e39150. 2012
    ..We investigated the effect of serotype on clinical presentation, outcome, and quality of life lost from invasive pneumococcal disease (IPD) in the context of the 7, 10, and 13 valent pneumococcal conjugate vaccines (PCV7, PCV10, PCV13)...
  39. ncbi request reprint Role of PCR in the diagnosis of pertussis infection in infants: 5 years' experience of provision of a same-day real-time PCR service in England and Wales from 2002 to 2007
    Norman K Fry
    Respiratory and Systemic Infection Laboratory, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London, UK
    J Med Microbiol 58:1023-9. 2009
    ..Real-time PCR is an invaluable tool both for enhanced epidemiological surveillance and for the provision of a rapid diagnosis of pertussis where results can affect patient and contact management...
  40. ncbi request reprint Post-licensure safety of the meningococcal group C conjugate vaccine
    Nick Andrews
    Statistics Unit, Health Protection Agency, Centre for Infections, London, UK
    Hum Vaccin 3:59-63. 2007
    ..15 (0.80-1.67). There was evidence of an increased risk of convulsions and idiopathic thrombocytopenic purpura following MMR vaccination as previously documented...
  41. doi request reprint Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database
    Julia Stowe
    Immunisation Department, Health Protection Agency Centre for Infections, London, UK
    Am J Epidemiol 169:382-8. 2009
    ....
  42. ncbi request reprint Evolution of surveillance of measles, mumps, and rubella in England and Wales: providing the platform for evidence-based vaccination policy
    A J Vyse
    PHLS Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
    Epidemiol Rev 24:125-36. 2002
  43. doi request reprint The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England
    Albert Jan van Hoek
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Services, Colindale, Health Protection Agency, London NW9 5EQ, UK
    Vaccine 30:7205-13. 2012
    ....
  44. ncbi request reprint The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children
    Ifeanyichukwu O Okike
    Vaccine Institute, St George s, University of London, London, United Kingdom
    Vaccine 29:6636-40. 2011
    ..There were no published data available regarding the immunogenicity of this vaccine in such children...
  45. doi request reprint No evidence of an increase of bacterial and viral infections following Measles, Mumps and Rubella vaccine
    Julia Stowe
    Immunisation Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
    Vaccine 27:1422-5. 2009
    ....
  46. doi request reprint Meningococcal C conjugate vaccine: the experience in England and Wales
    Helen Campbell
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK
    Vaccine 27:B20-9. 2009
    ..The MCC immunization programme has been extremely successful in controlling serogroup C disease and continues to be evaluated. The aim of this paper is to review the experiences in England and Wales over the past 9 years...
  47. doi request reprint Immunoglobulin G deficiency in United kingdom children with invasive pneumococcal disease
    Elaine Stanford
    Vaccine Evaluation Unit, Health Protection Agency, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, United Kingdom
    Pediatr Infect Dis J 30:462-5. 2011
    ....
  48. ncbi request reprint Epidemiology of invasive and other pneumococcal disease in children in England and Wales 1996-1998
    E Miller
    Immunization Division, Communicable Disease Surveillance Centre, London
    Acta Paediatr Suppl 89:11-6. 2000
    ..The incidence of admission for pneumococcal meningitis (1.9 overall and 19.6 for infants < 1 y of age) was similar to that derived from laboratory reports and resulted in an average duration of stay of 2 wk...
  49. pmc Sero-epidemiology of mumps in western Europe
    A Nardone
    PHLS Communicable Disease Surveillance Centre, 61 Colindale Avenue, London, NW9 SEQ, UK
    Epidemiol Infect 131:691-701. 2003
    ..Sero-surveillance of mumps is an important component of disease control and its usefulness will be enhanced by the development of an international mumps standard...
  50. ncbi request reprint Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers
    P Richmond
    Immunisation Division, Communicable Disease Surveillance Centre, Public Health Laboratory Service, London, United Kingdom
    J Infect Dis 183:160-3. 2001
    ..This evidence justified the use of a single dose in a catch-up immunization program for children 1-18 years old...
  51. ncbi request reprint Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England
    Albert Jan van Hoek
    Immunisation, Hepatitis and Blood Safety Department, Public Health England, London NW9 5EQ, England, United Kingdom Electronic address
    Vaccine 32:4349-55. 2014
    ..In April 2010 the 7-valent pneumococcal conjugate vaccine (PCV7) was replaced by the 13-valent PCV. We investigated pneumococcal carriage in children eligible for PCV7 or PCV13 and their household contacts...
  52. ncbi request reprint Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40
    Wendy A Knowles
    Enteric, Respiratory and Neurological Virus Laboratory, Specialist and Reference Microbiology Division, Health Protection Agency, Colindale, London, United Kingdom
    J Med Virol 71:115-23. 2003
    ..There is no serological evidence that SV40 entered the human population during the past 80 years, and the possibility of cross-reaction with BKV or JCV antibody must be considered...
  53. doi request reprint A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark
    Nick Andrews
    Statistics Modelling and Economics Department, Health Protection Services, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom
    Vaccine 30:3042-6. 2012
    ..The study therefore shows the potential for vaccine safety collaborations across Europe to detect true associations through use of common protocols and sharing of results or data...
  54. ncbi request reprint Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era
    Caroline Trotter
    Immunisation Division, PHLS Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ, UK
    Vaccine 21:1094-8. 2003
    ..This study provides baseline antibody levels which will facilitate the evaluation of the meningococcal serogroup C conjugate vaccination programme...
  55. doi request reprint No effect of 2008/09 seasonal influenza vaccination on the risk of pandemic H1N1 2009 influenza infection in England
    Richard Pebody
    Health Protection Agency Centre for Infections, 61 Colindale Avenue, UK
    Vaccine 29:2613-8. 2011
    ..Vaccine effectiveness did not differ significantly by age-group or hospitalisation status. There was no evidence prior vaccination with TIV significantly altered subsequent risk of pandemic influenza H1N1 2009 infection...
  56. pmc A novel method of oral fluid collection to monitor immunity to common viral infections
    M C Morris-Cunnington
    Immunisation Division, Communicable Disease Surveillance Centre, Health Protection Agency formerly Public Health Laboratory Service
    Epidemiol Infect 132:35-42. 2004
    ..This approach allowed the successful collection of comprehensive individual risk data, but response rates in adults must be improved if oral fluid surveys are to routinely complement serological surveillance...
  57. ncbi request reprint Validity of a reported history of chickenpox in targeting varicella vaccination at susceptible adolescents in England
    Nigel Field
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Services, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom 1 Research Department of Infection and Population Health, University College London, Mortimer Market Centre, off Capper Street, London WC1E 6JB, United Kingdom Electronic address
    Vaccine 32:1213-7. 2014
    ..To inform this approach, we estimated the proportion of adolescents with varicella antibodies by reported chickenpox history...
  58. doi request reprint Invasive pneumococcal disease, comorbidities, and polysaccharide vaccine use in children aged 5-15 years in England and Wales
    Shamez N Ladhani
    Immunisation, Hepatitis and Blood Safety Department, Public Health England, London
    Clin Infect Dis 58:517-25. 2014
    ..This study describes the epidemiology, serotype distribution, clinical characteristics, vaccination status, and reasons for nonvaccination in children aged 5-15 years with invasive pneumococcal disease (IPD)...
  59. pmc The social life of infants in the context of infectious disease transmission; social contacts and mixing patterns of the very young
    Albert Jan van Hoek
    Immunisation, Hepatitis and Blood Safety Department, Public Health England, London, England
    PLoS ONE 8:e76180. 2013
    ..The least contact was between adolescents and infants. Thus the impact of adolescent (pertussis) vaccination on infants would likely be limited, unless it reduces transmission to other age groups whose contact with infants is greater...
  60. doi request reprint Health and economic impact of the seasonal influenza vaccination programme in England
    Marc Baguelin
    Health Protection Agency, United Kingdom
    Vaccine 30:3459-62. 2012
    ..The seasonal influenza vaccination programme in England targets individuals over 65 years old and in clinical risk groups...
  61. pmc Comparison of rubella seroepidemiology in 17 countries: progress towards international disease control targets
    Anthony Nardone
    Centre for Infections, Health Protection Agency, London, England
    Bull World Health Organ 86:118-25. 2008
    ..To standardize serological surveillance to compare rubella susceptibility in Australia and 16 European countries, and measure progress towards international disease-control targets...
  62. doi request reprint Guillain-Barré syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: self-controlled case series
    Nick Andrews
    Statistics Modelling and Economics Department, Health Protection Services, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom
    Vaccine 29:7878-82. 2011
    ..05 [95% confidence interval (CI) 0.37 to 2.24]). We found no evidence of an increased risk of GBS in the 6 weeks following pandemic influenza vaccination...
  63. pmc Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England
    Nick Andrews
    Immunisation Division, PHLS Communicable Disease Surveillance Centre, London NW9 5EQ, United Kingdom
    Clin Diagn Lab Immunol 10:780-6. 2003
    ....
  64. pmc No increased risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome
    Brent Taylor
    General and Adolescent Paediatric Unit, Institute of Child Health, University College London, London, UK
    Arch Dis Child 92:887-9. 2007
    ..To investigate whether meningococcal C conjugate vaccine (MCCV) caused relapse in children with steroid-responsive nephrotic syndrome...
  65. ncbi request reprint New estimates of herpes simplex virus type 2 seroprevalence in England: 'high' but stable seroprevalence over the last decade
    Marianne Morris-Cunnington
    Immunisation Division, Communicable Disease Surveillance Centre, London, UK
    Sex Transm Dis 31:243-6. 2004
    ..This study aimed to ascertain trends in HSV-2 infection in England between 1991 and 2000...
  66. ncbi request reprint Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults
    David Goldblatt
    Immunobiology Unit, Institute of Child Health, Public Health Laboratory Service, Communicable Disease Surveillance Centre, London, United Kingdom
    J Infect Dis 185:397-400. 2002
    ....
  67. ncbi request reprint A population-based seroprevalence study of hepatitis A virus using oral fluid in England and Wales
    M C Morris-Cunnington
    Communicable Disease Surveillance Centre, Health Protection Agency, London, UK
    Am J Epidemiol 159:786-94. 2004
    ..1% and to 12.1% in unvaccinated individuals. The availability of comprehensive risk factor data allowed the description of two risk profiles related to natural infection and vaccination...
  68. ncbi request reprint Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization
    D Goldblatt
    Institute of Child Health, and Immunisation Division, Communicable Disease Surveillance Centre, London, United Kingdom
    J Infect Dis 177:1112-5. 1998
    ..Antibody avidity may help distinguish, in persons with low antibody titers, between those who are primed for memory and those who are not...
  69. ncbi request reprint Mumps surveillance in England and Wales supports introduction of two dose vaccination schedule
    N Gay
    Immunisation Division, PHLS Communicable Disease Surveillance Centre, London
    Commun Dis Rep CDR Rev 7:R21-6. 1997
    ..A second dose of vaccine, which is now being offered to preschool children, will reduce morbidity and should eventually eliminate mumps if coverage is high enough...
  70. ncbi request reprint The epidemiology of measles in England and Wales since the 1994 vaccination campaign
    N Gay
    Immunisation Division, PHLS Communicable Disease Surveillance Centre, London
    Commun Dis Rep CDR Rev 7:R17-21. 1997
    ..The two dose vaccination programme should maintain the herd immunity of the population and the elimination of endemic measles transmission...
  71. ncbi request reprint Oral fluid collection by post--a pilot study of two approaches
    M C Morris
    Immunisation Division, PHLS Communicable Disease Surveillance Centre, London, UK
    Public Health 116:113-9. 2002
    ..In the other age groups additional reminders could prove a cost-effective way of increasing the response rate further...
  72. ncbi request reprint Bell's palsy and parenteral inactivated influenza vaccine
    Julia Stowe
    Immunisation Department, Health Protection Agency Centre for Infections, London, UK
    Hum Vaccin 2:110-2. 2006
    ..78-1.08). There was also no evidence of an increased risk in any age group or following pneumococcal vaccine. A significant increase was seen on the day of vaccination (day 0) probably due to opportunistic recording of cases...
  73. ncbi request reprint Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association
    Nick Andrews
    Statistics Unit, Health Protection Agency, Communicable Disease Surveillance Centre, London, United Kingdom
    Pediatrics 114:584-91. 2004
    ....
  74. doi request reprint Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: a database study
    Julia Stowe
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom
    Vaccine 29:9467-72. 2011
    ..These results neither provide evidence of an increased risk of convulsions following TIV over a 10-year surveillance period nor following a single dose of the ASO3 adjuvanted monovalent H1N1 vaccine in 2009/10...
  75. doi request reprint Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/haemophilus influenza type b/polio vaccine in the United Kingdom
    Nick Andrews
    Statistics Unit, Health Protection Agency, Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
    Vaccine 28:7215-20. 2010
    ..Although there were no other significant differences between vaccines the relative incidence was significantly above one on the day of vaccination for convulsions following DTwP/Hib and for apnoea/collapse following DTaP(5)/Hib/IPV...
  76. ncbi request reprint Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers
    Jo Southern
    Immunisation Department, Communicable Disease Surveillance Centre, Health Protection Agency, 61 Colindale Avenue, Colindale, London, UK
    Vaccine 23:3829-35. 2005
    ....
  77. ncbi request reprint Laboratory diagnosis of pertussis infections: the role of PCR and serology
    Norman K Fry
    Respiratory and Systemic Infection Laboratory and Special Projects Laboratory, Health Protection Agency, 61 Colindale Avenue, London NW9 5HT, UK
    J Med Microbiol 53:519-25. 2004
    ..Rapid diagnosis of B. pertussis infection particularly in infants by PCR, together with serological assays, can enhance surveillance systems for pertussis in all age groups...
  78. ncbi request reprint Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction
    Caroline L Trotter
    Statistics, Economics, and Modelling Department, Health Protection Agency Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ, UK
    Lancet 364:365-7. 2004
    ..The number of individuals in these cohorts remains low, but alternative routine immunisation schedules should be considered to ensure high levels of protection are sustained...
  79. doi request reprint The cost-effectiveness of vaccinating pregnant women against seasonal influenza in England and Wales
    Mark Jit
    Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 6BT, United Kingdom
    Vaccine 29:115-22. 2010
    ..Key sources of uncertainty are the cost of vaccine delivery and the quality of life detriment due to a clinically apparent episode of confirmed influenza. The cost of vaccine purchase itself is relatively low...
  80. ncbi request reprint Long-term protection in children with meningococcal C conjugate vaccination: lessons learned
    Ray Borrow
    Vaccine Evaluation Unit, NW Regional HPA Laboratory, Manchester Medical Microbiology Partnership, PO Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester, M13 9WZ, UK
    Expert Rev Vaccines 5:851-7. 2006
    ..The assumption that immune memory was predictive of long-term protection is incorrect, at least after vaccination in infancy. Persistence of antibody and herd immunity may be more relevant for long-term disease control...
  81. doi request reprint Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy
    Jamie Findlow
    Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Royal Infirmary, Manchester, UK
    Clin Infect Dis 51:1127-37. 2010
    ..7-2,4). In this trial, we assessed the immunogenicity of these formulations in infants, who are at greatest risk of contracting MenB disease...
  82. pmc Immunoglobulin G subclass response to a meningococcal quadrivalent polysaccharide-diphtheria toxoid conjugate vaccine
    Helen Findlow
    Vaccine Evaluation Unit, Health Protection Agency North West, P O Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester, M13 9WZ, United Kingdom
    Clin Vaccine Immunol 13:507-10. 2006
    ..Further studies on IgG subclasses following meningococcal polysaccharide and conjugate vaccination are needed...
  83. pmc Serotype-specific immune unresponsiveness to pneumococcal conjugate vaccine following invasive pneumococcal disease
    Ray Borrow
    Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester M13 9XZ, United Kingdom
    Infect Immun 76:5305-9. 2008
    ..This serotype-specific unresponsiveness may reflect immune paralysis due to large pneumococcal polysaccharide antigen loads and/or a potential genetic basis for nonresponse to individual pneumococcal serotypes...
  84. ncbi request reprint Meningococcal surrogates of protection--serum bactericidal antibody activity
    Ray Borrow
    Meningococcal Reference Unit, Health Protection Agency North West Laboratory, Manchester Royal Infirmary, Manchester M13 9WZ, UK
    Vaccine 23:2222-7. 2005
    ..SBA activity as a correlate of protection for evaluating the immune response to meningococcal vaccines is described in this review...
  85. pmc Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac
    Jamie Findlow
    Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, United Kingdom
    Infect Immun 74:4557-65. 2006
    ..These results emphasize the need for standardized methodologies that would allow a more robust comparison of assays between laboratories and promote their further evaluation as correlates of protection against MenB disease...
  86. ncbi request reprint The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region
    A Nardone
    Health Protection Agency, Centre for Infections, London, UK
    Vaccine 25:7866-72. 2007
    ..There are substantial differences in VZV sero-epidemiology within the European region, which will need to be taken into account in designing national policies regarding VZV vaccination...
  87. ncbi request reprint Review of the effect of measles vaccination on the epidemiology of SSPE
    H Campbell
    Immunisation Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK
    Int J Epidemiol 36:1334-48. 2007
    ..We conducted a comprehensive review of the impact of measles immunization on the epidemiology of SSPE and examined epidemiological evidence on whether there was any vaccine-associated risk...
  88. pmc Serum antibody kinetics following nasal or parenteral challenge with meningococcal polysaccharide in healthy adults
    H Findlow
    Vaccine Evaluation Unit, Health Protection Agency, Manchester Medical Microbiology Partnership, P O Box 209, Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom
    Clin Vaccine Immunol 18:424-9. 2011
    ....
  89. doi request reprint A comparison of hepatitis B seroepidemiology in ten European countries
    A Nardone
    Centre for Infections, Health Protection Agency, London, UK
    Epidemiol Infect 137:961-9. 2009
    ..Regular serological surveys to ascertain HBV status within a population, such as reported here, provide important data to assess the need for and to evaluate universal HBV vaccination programmes...
  90. pmc Prevalence of human papillomavirus antibodies in young female subjects in England
    M Jit
    Immunisation Department, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5HT, UK
    Br J Cancer 97:989-91. 2007
    ..7% (95% confidence intervals 9.0-12.3) for human papillomavirus (HPV) 6, 2.7% (1.8-3.6) for HPV 11, 11.9% (10.2-13.6) for HPV 16, 4.7% (3.5-5.8) for HPV 18, and 20.7% (18.6-22.7) for any of the four types...
  91. ncbi request reprint Respiratory syncytial virus infection in infants admitted to paediatric intensive care units in London, and in their families
    N S Crowcroft
    Immunisation Department, Health Protection Agency, Centre for Infections, London, NW9 5EQ, UK
    Eur J Pediatr 167:395-9. 2008
    ..Young infants are most often infected at the same time as or before their parents and siblings, indicating that the source may be outside the household; vaccinating family members may not prevent RSV infection in infants...
  92. pmc The changing epidemiological pattern of hepatitis A in England and Wales
    M C Morris
    Immunisation Division, PHLS Communicable Disease Surveillance Centre, London
    Epidemiol Infect 128:457-63. 2002
    ..Further population-based surveys collecting more in-depth social and demographic data are needed to confirm the main factors influencing hepatitis A seroprevalence and to explain the regional differences...
  93. pmc The burden of Helicobacter pylori infection in England and Wales
    A J Vyse
    Immunisation Division, PHLS Communicable Disease Surveillance Centre, London, UK
    Epidemiol Infect 128:411-7. 2002
    ..These data suggest H. pylori infection is becoming less common, is acquired at an early age and is unlikely to be resolved unless suitable antimicrobial treatment is sought...
  94. pmc Severe and unrecognised: pertussis in UK infants
    N S Crowcroft
    Immunisation Division, HPA Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ, UK
    Arch Dis Child 88:802-6. 2003
    ..To diagnose pertussis using culture, polymerase chain reaction, and serology, in children admitted to intensive care units (PICUs) and some paediatric wards in London, and in their household contacts to determine the source of infection...
  95. ncbi request reprint Sero-epidemiology of Bordetella pertussis in England and Wales
    A Nardone
    Immunisation Division, Communicable Disease Surveillance Centre, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK
    Vaccine 22:1314-9. 2004
    ..There is an important incidence of infection in the population, which is greater amongst children than adults, but there is only limited evidence of a correlation with epidemic cycles...
  96. pmc Seroprevalence of antibody to varicella zoster virus in England and Wales in children and young adults
    A J Vyse
    Health Protection Agency Sero Epidemiology Unit, Immunisation Division, Communicable Disease Surveillance Centre, London, UK
    Epidemiol Infect 132:1129-34. 2004
    ..This was shown to be a more accurate approach to categorizing data from an epidemiological perspective...
  97. pmc Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains
    P Richmond
    Immunisation Division, Communicable Disease Surveillance Centre, Public Health Laboratory Service, London NW9 5EQ, United Kingdom
    Infect Immun 69:2378-82. 2001
    ..MCC-TT vaccine is highly immunogenic and primes for immunologic memory against OAc+ and OAc- MenC strains in infancy...
  98. pmc The seroepidemiology of Bordetella pertussis infection in Western Europe
    R G Pebody
    Immunisation Department, Health Protection Agency HPA Communicable Disease Surveillance Centre, London, UK
    Epidemiol Infect 133:159-71. 2005
    ....
  99. ncbi request reprint Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine
    J Southern
    Immunisation Department, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK
    Vaccine 24:215-9. 2006
    ..These results suggest that a reduced number of doses of MCC-TT would be adequate in infancy if given concomitantly with an acellular pertussis-containing vaccine...
  100. pmc Interpreting serological surveys using mixture models: the seroepidemiology of measles, mumps and rubella in England and Wales at the beginning of the 21st century
    A J Vyse
    Health Protection Agency, Centre for Infections, Sero Epidemiology Unit, Immunisation Department, London, UK
    Epidemiol Infect 134:1303-12. 2006
    ..Investigations into the efficacy of two doses of a mumps containing vaccine should be a priority during the current epidemic...
  101. ncbi request reprint Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005
    R Borrow
    Vaccine Evaluation Unit, Health Protection Agency, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom
    Vaccine 24:5093-107. 2006